Marinus Pharmaceuticals (MRNS) Sets New 52-Week High at $8.75

Marinus Pharmaceuticals Inc (NASDAQ:MRNS)’s share price hit a new 52-week high during trading on Thursday . The company traded as high as $8.75 and last traded at $6.19, with a volume of 1530000 shares. The stock had previously closed at $6.69.

MRNS has been the subject of a number of recent research reports. ValuEngine downgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. JMP Securities reissued an “outperform” rating and issued a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 12th. Finally, BidaskClub downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.02.

A number of large investors have recently modified their holdings of MRNS. KCG Holdings Inc. raised its stake in Marinus Pharmaceuticals by 29.5% in the first quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 14,692 shares in the last quarter. Jennison Associates LLC raised its stake in Marinus Pharmaceuticals by 108.1% in the second quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock worth $1,112,000 after buying an additional 421,600 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Marinus Pharmaceuticals in the third quarter worth approximately $128,000. EAM Investors LLC bought a new position in Marinus Pharmaceuticals in the third quarter worth approximately $554,000. Finally, Citadel Advisors LLC increased its position in shares of Marinus Pharmaceuticals by 327.8% during the third quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 39,371 shares in the last quarter. 49.77% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/12/07/marinus-pharmaceuticals-mrns-sets-new-52-week-high-at-8-75.html.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply